Breaking News
Sort by:
Date
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
BICO’s CYTENA Signs USD 10 Million Deal to Distribute Single Cell Isolators in China to Accelerate Development of Next Generation Therapies
Today CYTENA, a BICO company, announced it has signed a 2-year deal with Applitech Pharmaceutical Equipment Technology to […]
CYTENA Launches C.STATION, a Fully Automated Platform for Stable Cell Line Development to Streamline Production of Antibody and Gene Therapies
Today CYTENA, a BICO company, launched C.STATION, a new platform for fully automated stable cell line development. The […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more